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and Herbert Sch€ ochl 1, 7 BACKGROUND: During massive hemorrhage, it is recommended to transfuse red blood cells, platelet concentrate, and fresh-frozen plasma in a ratio close to 1:1:1. To avoid the thawing process of fresh frozen plasma, lyophilized plasma (LP) is increasingly used. Evidence is limited on the activity of coagulation factors in reconstituted blood using LP and concentrated LP versions.
STUDY DESIGN AND METHODS:
Whole blood from ten healthy volunteers was separated into red blood cell, fresh frozen plasma, and platelet concentrate units. Aliquots of red blood cells and plasma concentrate were mixed with either fresh frozen plasma (200 mL) or LP at reconstitution ratios of 2:1:1, 1:1:1, and 1:1:2. LP was used either at the recommended standard volume of 200 mL (LP200) or was more concentrated at volumes of 100 and 50 mL (LP100 and LP50, respectively). The hemostatic capacity of each reconstituted whole blood sample was tested with blood cell counts, standard coagulation tests, factor activity, thrombin generation, and viscoelastic assays.
RESULTS:
Hematocrit, platelet counts, and fibrinogen levels of the three ratios were similar between FFP200 and LP200 units but were lower compared with the corresponding ratios in LP100 and LP50 units. The activity of procoagulant and anticoagulant factors increased linearly with the increasing plasmatic fraction and, at 1:1:2 ratio, was significantly higher in LP50 units compared with FFP200 and LP200 units. Thrombin generation was similar throughout the four plasma groups at any ratio.
CONCLUSIONS:
Decreasing the dilution volume of LP facilitates reaching higher hematocrit and coagulation protein levels without a relevant increase in thrombin generation. This is due to preserved balance between procoagulant and anticoagulant factors in the concentrated LP preparations.
ABBREVIATIONS: ETP 5 endogenous thrombin potential;
LP 5 lyophilized plasma; LP100 5 lyophilized plasma unit dissolved in 100 mL sterile water; LP200 5 lyophilized plasma unit dissolved in 200 mL sterile water; LP50 5 lyophilized plasma unit dissolved in 50 mL sterile water; MCF 5 maximum clot firmness; RWB 5 reconstituted whole blood. S evere hemorrhage is a life-threatening condition and accounts for roughly one-half of early traumatic deaths. [1] [2] [3] Hemostatic derangement, termed acute coagulopathy of trauma, starts soon after the insult, led by hypoperfusion, endothelial dysfunction, inflammation, and activated protein C-mediated hyperfibrinolysis. [4] [5] [6] [7] The depletion of coagulation factors, and especially low fibrinogen levels resulting from ongoing blood loss and dilution with resuscitation fluids, aggravates coagulopathy and promotes diffuse microvascular bleeding. [8] [9] [10] Massive transfusion protocols specifically addressing early coagulopathy were associated with better outcomes, and many trauma centers accordingly changed their policies to higher and earlier use of fresh frozen plasma (FFP). 11, 12 Furthermore, recent reports suggest improved outcome or shorter time to hemostasis associated with a higher plasma to red blood cell (RBC) ratio (close to 1:1). 1, 13 Nevertheless, the thawing process before transfusion is time consuming, 14 and only busy trauma centers can afford to store prethawed plasma for immediate use, whereas never-frozen liquid plasma has been used only anecdotally 15 but might be a valid alternative.
However, reconstitution of whole blood in a 1:1:1 (RBC:platelets concentrate [PC]:plasma) ratio leads to dilution of both hematocrit and coagulation factors by the addition of preservatives and anticoagulants (which are unavoidably present in each blood component). 16, 17 Other options to adhere to the 1:1:1 transfusion concept are the use of lyophilized plasma (LP), special freeze-dried plasma that can be stored at room temperature and rapidly reconstituted on demand, 18, 19 or transfusion of fresh whole blood, which proved to be effective in a military setting. 20, 21 In contrast, some centers in Europe use fibrinogen concentrates to rapidly restore this key element of hemostasis. 22, 23 In the current study, we reconstituted whole blood (RWB) adding either FFP or a commercially available LP to the cellular components (RBC and PC). Multiple reconstitution ratios of RBC:PC:plasma (2:1:1, 1:1:1, and 1:1:2) as well as three different concentrations of LP were studied. All samples were tested with different assays: blood cell counts, standard coagulation tests, coagulation factors activity, endogenous thrombin potential (ETP), and thromboelastometry. The aim of the current study was to investigate the impact of different reconstitution ratios as well as different concentrations of LP on the potential hemostatic capacity of such reconstituted blood samples. 
MATERIALS AND METHODS

RWB-study groups
Volumes of the single blood components were standardized according to the average delivery volume of the blood bank to 240 mL for RBCs, 50 mL for PC, and 200 mL for FFP. FFP was thawed (Plasmatherm; Barkey Medizintechnik GmbH) and used within 2 hours according to the experimental protocol. To achieve three different concentrations of lyophilized plasma, the vial of LyoPlas N-w was first dissolved in 50 mL distilled water (the LP50 group), and aliquots of this solution were subsequently diluted 1:1 and 1:3 with additional distilled water to produce samples for the LP100 and LP200 groups, respectively. Each aliquot of LyoPlas was used within 2 hours after reconstitution. The study samples of RWB were obtained by mixing aliquots of single blood components at ratios of 2:1:1, 1:1:1, and 1:1:2 (RBC:PC:plasma), thus constituting the 12 total study groups. To reduce age-related variability of blood components, 9-day-old RBC and FFP units (same donor) and 2-day-old PC units (different donor) were used throughout the study.
Blood cell counts and standard coagulation tests
Each reconstituted study sample as well as the original RBC and PC units underwent complete cell counts (Sysmex XE-2100; Sysmex Europe GmbH). Standard coagulation tests were performed on each reconstituted study sample after centrifugation at 1882 3 g for 20 minutes (Multifuge 1S, Heraeus; ThermoFisher Scientific) and on the source FFP and LP units. These tests included: prothrombin time (PT) (Thromborel S), activated partial thromboplastin time (aPTT) (Pathromtin SL), and Clauss fibrinogen concentration (Multifibren U) on a standard laboratory coagulometer (BCS XP system and reagents from Siemens Healthcare Diagnostics GmbH).
Viscoelastic tests
Viscoelastic testing was carried out using rotational thromboelastometry (ROTEM) (Tem International). For this purpose, the extrinsically activated assay with recombinant tissue factor (EXTEM) and the extrinsically activated assay with cytochalasin D (FIBTEM) were performed. The ROTEM measurement parameters clotting time (CT), a angle, and maximum clot firmness (MCF) were selected for analysis. ROTEM tests were run for 60 minutes after initiation of clot formation.
Single coagulation factor activity and ETP
The activity of single coagulation factors and ETP were analyzed on the BCS-XP system. For this purpose, RWB aliquots were centrifuged (1882 3 g for 20 min; Multifuge 1S, Heraeus; ThermoFisher Scientific) to create plateletfree plasma samples that were subsequently stored at 2808C before further analysis. The activity of coagulation Factors II, V, VII, VIII, IX, X, XI, and XII was determined using a coagulometric method (coagulation-deficient plasmas; Siemens Healthcare Diagnostics). A chromogenic assay was used to determine the activity of coagulation factor XIII (Berichrom FXIII; Siemens Healthcare Diagnostics GmbH), antithrombin, and protein C (HemosIL; Instrumentation Laboratory Company). For acquisition of ETP, a kinetic chromogenic measurement with subsequent calculation of the area under the curve was used (INNOVANCE ETP; Siemens Healthcare Diagnostics).
Statistics
The sample size of 10 was chosen according to previous experience of the authors and other published studies. 16, 24 Data distribution was assessed using the KolmogorovSmirnov test. Means and standard deviations are reported for normally distributed data, and medians and interquartile ranges are used for non-normally distributed data. One-way analyses of variance and Bonferroni post-hoc comparisons or Kruskal-Wallis tests and Dunn's post hoc comparisons (for normally and nonnormally distributed data, respectively) were applied to assess differences within the four plasma groups (i.e., comparing different ratios within the same group) and between the four plasma groups (i.e., comparing different plasma groups within the same ratio). A two-tailed p value < 0.05 was considered statistically significant. Statistical calculations were performed using GraphPad Prism version 5 (GraphPad Software).
RESULTS
Characterizations of blood cell counts, standard coagulation tests, fibrinogen levels, and the activity of single coagulation factors in the blood components before mixing in RWB are available in Tables S1, S2 , and S3 (available as supporting information in the online version of this paper). Concerning the RWB aliquots, the median hematocrit decreased significantly from the 2:1:1 ratio to the 1:1:2 ratio within the different plasma groups. The hematocrit of the LP100 and LP50 groups was also significantly higher compared with that of the FFP200 and LP200 groups at every ratio investigated (Table 1) . Conversely, median fibrinogen levels at the 1:1:2 ratio were significantly higher than the corresponding values at the 2:1:1 ratio; furthermore, fibrinogen levels at the 1:1:2 ratio in the LP50 group (265 mg/dL) were significantly higher than levels in the FFP200 and LP200 groups (215 mg/dL and 210 mg/dL, respectively) at the same ratio. Standard coagulation test prothrombin time (PT0 [quick] ) values also increased progressively with increasing plasmatic fraction of the RWB aliquots, exceeding the lower reference level in the FFP200, LP100, and LP50 groups only (at the 1:1:1 and 1:1:2 ratios). Similarly, the majority of aPTT results were outside the upper reference level. A trend toward reduction of the aPTT levels with increasing plasmatic fraction was present in all groups except for LP50 (Table 1 ). Figure  1 illustrates the main parameters of thromboelastometry: In Figure 1A , the CT for the EXTEM assay was significantly shortened from the 2:1:1 ration to the 1:1:2 ratio in all groups except for LP50. Indeed, the CT did not decrease further from 1:1:1 to 1:1:2 in LP50 aliquots, and the median CT of the latter aliquots was significantly higher than the corresponding aliquots of the other groups. In Figure  1B ,C, the EXTEM speed of clot formation (a angle) and MCF improved significantly improved from the 2:1:1 ratio to the 1:1:2 ratio throughout all groups. FIBTEM MCF, a parameter that specifically reflects fibrinogen content and functionality, was also significantly increased in the 1:1:2 aliquots (vs. the 2:1:1 aliquots) throughout all groups. In addition, as observed in Figure 1B ,C,D, we detected significant differences between aliquots of LP200, LP100, and LP50 units (values were higher in LP100 and LP50 units compared with LP200 units).
A complete analysis of the activity of single coagulation factors is displayed in Table 2 . At a 1:1:1 ratio, LP200 units had generally lower mean coagulation factor activity (p < 0.05 for Factors VIII, IX, and XI) than FFP200 units. Adding one aliquot of either RBCs or plasma to the 1:1:1 aliquots accordingly shifted the overall activity of coagulation factors toward a lower or higher level in all groups. At the 1:1:2 ratio, LP100 aliquots resulted in a (generally) significant increase in factor activity compared with the nonconcentrated LP (LP200) aliquots; an analysis of the activity of procoagulant and anticoagulant factors in the highest LP concentration tested (LP50) revealed significantly increased factor activity compared with the other plasma groups. The activity of anticoagulant factors (antithrombin and protein C) was proportionate to that of procoagulant factors in every combination explored. This result can be also appreciated from Figure 2 , in which the activity of Factor II in each group is compared with that of antithrombin.
Concordant with the activity of coagulation factors, ETP increased from the 2:1:1 ratio to the 1:1:2 ratio in every group (even if not significantly in the LP50 group) (Fig. 3) . ETP values did not differ between plasma groups, with the exception of higher ETP in FFP200 units compared with LP200 units at the 2:1:1 ratio. Finally, in Figure  4 , the relationships between hematocrit and Factor II levels and between hematocrit and fibrinogen levels are depicted.
DISCUSSION
To the best of our knowledge, this is the first study to provide a wide characterization of the hemostatic potential in reconstituted blood using various ratios and different LP concentrations. The most striking result of this study is that aliquots from the LP100 and LP50 groups did not show increased thrombin-generation potential despite the higher factor activity. This finding most likely is because of preserved balance between the main procoagulant and anticoagulant factors.
Concordant with the related literature, 16, 17, 25 whole blood reconstituted at a 1:1:1 ratio had only limited oxygen-carrying capacity (median hematocrit, 30% in both FFP200 and LP200) and reduced coagulation proteins (compared with the pure FFP or LP units) because of the mutual dilution of RBCs, plasma, and platelets. The use of low-volume LPs allowed us to reduce the extent of dilution on the cellular count (higher hematocrit and platelet count) and coagulation factors (increased fibrinogen and both procoagulant and anticoagulant levels) compared with the other two groups. The finding of preserved balance of the procoagulant and anticoagulant proteins is in agreement with the results from a rat model of hemorrhagic-traumatic shock by Cardenas and coworkers, who demonstrated that resuscitation with FFP resulted in a reversal of the hypercoagulable state, reflected by a reduction in previously enhanced thrombin-generation parameters. 26 Conversely, the rats that were resuscitated with crystalloids maintained the exaggerated ETP values. Researchers attributed the observed difference to the significantly higher antithrombin content after resuscitation in the FFP group. Upon severe bleeding and trauma, coagulation factors undergo loss, consumption, and dilution caused by resuscitation with nonhemostatic fluids. The first coagulation factor to reach critical values in this setting is fibrinogen, 27 and hypofibrinogenemia is associated with poor outcomes. 28, 29 In this respect, another important message of our study is that it is almost impossible to achieve the fibrinogen values recommended by recent guidelines 30, 31 when adopting a 2:1:1 or 1:1:1 ratio during massive transfusion, according to the mathematical model developed by Collins and colleagues. 32 Indeed, both European and American guidelines on the management of major bleeding suggest increasing fibrinogen levels to between 150 and 200 mg/dL in the actively bleeding patient. In our model, adopting a 1:1:2 ratio determined only a slight increase of fibrinogen levels, but at the expenses of a reduction in hematocrit (as depicted in Fig. 4) ; we further demonstrated that the low-volume LP strategy confers limited further advantage in terms of Clauss fibrinogen levels, and we could speculate that fibrinogen concentrates or cryoprecipitate might provide the right load of fibrinogen to bleeding patients. 32 Lee and coworkers recently challenged full-volume versus half-volume LP in a pig polytrauma and hemorrhagic shock model. 33 The half-volume LP group (similar to our LP100 group) also had increased levels of coagulation proteins (including fibrinogen) compared with the full-volume LP group (i.e., LP200 in our model). Low-volume LP proved to be safe and effective in this context, because every animal allocated to this preparation survived the infusion and had similar resuscitation endpoints compared with animals allocated to full-volume LP. Despite this, the authors found no significant difference between the two study groups in viscoelastic parameters assessed by thromboelastography, in analogy with the results reported by Khan and colleagues in a cohort of trauma patients. 34 The limited usefulness of the standard coagulation tests (PT and aPTT) in driving the transfusion requirements of bleeding patients has already been pointed out 35, 36 ; accordingly, we observed that both standard coagulation tests were repeatedly outside the reference limits, even when ETP values were "normal" (75%-100%). Conversely, the viscoelastic analysis revealed a shortening of CT and increased clot strength for higher plasma:RBC ratios. It is noteworthy that the EXTEM and FIBTEM tests in the LP100 and LP50 aliquots were similar to those in the other groups (with somewhat higher values of FIBTEM MCF compared with the LP200 group), and no macroscopic particle or aggregate was evident in the lowvolume LP solutions, suggesting that coagulation factors and fibrinogen were properly dissolved. In this regard, it is worth emphasizing the experimental nature of our study and that, even if we could obtain well-dissolved admixtures in both LP100 and LP50 groups, more preclinical research is needed to possibly translate this approach to the clinical context. As previously demonstrated by Ponschab and colleagues, 16 the FFP units had significantly higher content of factors compared with the LP200 units; this could result from either greater loss of coagulation factors during the manufacturing process 37 or simply from interdonor variability, because both FFP and LP units were prepared from single donations. This study has some limitations. The entirely in vitro setting, the small size, and the peculiar pool of donors (all male and Blood Group O) hinder the translatability of the results into clinical practice. At the same time, however, the wide range of coagulation tests certainly gives strength to our findings. Furthermore, we did not investigate the "purity" of the LP100 and LP50 solutions at the microscopic level but only relied on functional testing.
Another controversial aspect of using concentrated LP is the unavoidable increase in osmolarity and oncotic pressure of the corresponding RWB. An increase of osmolarity in the circulating compartment would be paralleled by an inward shift of free water into the circulating volume from the cellular and interstitial compartments. 38 This determines a dilution of the circulating blood volume, thus vanishing the effect of the concentrated plasma transfusion. However, it is worth considering that the above-mentioned effect is a dynamic process during which coagulation factors present in the concentrated RWB could immediately boost hemostasis at the site of injury. Nonetheless, despite some reports regarding the use of hyperosmolar LP in swine models, 33, 39 currently, there is a lack of evidence regarding the use of hyperosmolar RWB (as in our study) in vivo.
To conclude, we have demonstrated that RWB using more concentrated LP units allow delivery of the same total amount of factors without excessively diluting the hematocrit and platelet count. The preserved balance between procoagulant and anticoagulant factors of this admixture suggests potentially safe use in patients at risk for thrombotic events. Further studies comparing lowvolume LP with FFP and coagulation factor concentrates in both experimental and clinical settings are warranted. 
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